New Zealand markets closed

Acticor Biotech SAS (ALACT.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
3.8000+0.1700 (+4.68%)
At close: 05:35PM CEST
Full screen
Previous close3.6300
Open3.6800
Bid0.0000 x 0
Ask0.0000 x 0
Day's range3.6400 - 3.8000
52-week range2.7200 - 6.2200
Volume25,224
Avg. volume22,687
Market cap59.608M
Beta (5Y monthly)-0.38
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024

    PARIS, April 15, 2024--Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, focusing stroke, announces today its participation in the European Stroke Organization Conference (ESOC) 2024, to be held from 15 to 17 May 2024 in Basel, Switzerland.

  • Business Wire

    ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of March 31, 2024

    PARIS, April 05, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today discloses the total number of voting rights and shares as of March 31, 2024 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority).

  • Business Wire

    ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of February 29, 2024

    PARIS, March 18, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today discloses the total number of voting rights and shares as of February 29, 2024 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority).